Thank you, that makes sense after P3 trial.....I also view this as more likely if priced competitively with other approved drugs. How common is it for insurance to accept “off-label” scripts? Believe me, I am optimistic about our future, but I want to have realistic expectations.

I guess at the moment, revenues don’t matter that much, but if combo approval is delayed 3 months, would reduce 2020 revenues from $580M to $435M. I think mono or cancer could make up for some of this, but personally I want to plan for the worst and be positively surprised for anything better!